The XENERA™-1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Post-menopausal Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has Spread



Status:Recruiting
Conditions:Breast Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:4/5/2019
Start Date:November 28, 2018
End Date:January 12, 2022
Contact:Boehringer Ingelheim
Email:clintriage.rdg@boehringer-ingelheim.com
Phone:1-800-243-0127

Use our guide to learn which trials are right for you!

XENERA™-1: A Multi-centre, Double-blind, Placebo-controlled, Randomised Phase II Trial to Compare Efficacy of Xentuzumab in Combination With Everolimus and Exemestane Versus Everolimus and Exemestane in Post-menopausal Women With HR+ / HER2- Metastatic Breast Cancer and Non-visceral Disease

The main objective of the trial is to assess the anti-tumor activity of xentuzumab in
combination with everolimus and exemestane over everolimus and exemestane in post menopausal
patients with HR+/ HER2- advanced or metastatic breast cancer and non-visceral disease.


Inclusion Criteria:

- Documented histologically confirmed breast cancer with ERand/ or PgR-positive and
HER2-negative status

- Locally advanced or metastatic breast cancer not deemed amenable to curative surgery
or curative radiation therapy

- Archival tumour sample available at the time of informed consent and provided to the
central laboratory around the time of randomisation. Patients must provide a
formalin-fixed paraffin embedded (FFPE) tissue biopsy sample preferably taken at the
time of presentation with recurrent or metastatic disease (provision of a biopsy
sample taken from the bone is not acceptable).

- Patients must satisfy the following criteria for prior therapy:

- Progressed during treatment or within 12 months of completion of adjuvant therapy
with an aromatase inhibitor and/or tamoxifen if post-menopausal, or tamoxifen if
pre or peri-menopausal or

- Progressed while on or within 1 month after the end of prior aromatase inhibitor
therapy for advanced/metastatic breast cancer if post-menopausal, or prior
endocrine treatment for advanced/metastatic breast cancer if pre- or
peri-menopausal.

- Patients must not have received more than one previous line of non-steroidal aromatase
inhibitor treatment for advanced/metastatic disease. Prior treatment with one line of
CDK4/6 inhibitors is allowed.

- Prior treatment with fulvestrant if duration was at least 2 years in the adjuvant
setting or at least 6 months in the metastatic setting is allowed.

- Patients must be post-menopausal at time of signature of trial informed consent.

- Patients must have

- At least one measurable non-visceral lesion according to RECIST version 1.1 in
either lymph nodes, soft tissue, skin and/or

- At least one measurable non-visceral lesion according to RECIST version 1.1 as
lytic or mixed (lytic + blastic) in bone and/or

- At least one non-measurable lytic or mixed (lytic + blastic) bone lesion
according to RECIST version 1.1

- Eastern Cooperative Oncology Group (ECOG) performance score 0 or 1.

- Adequate organ function

Exclusion Criteria:

- Previous treatment with agents targeting the IGF pathway, PI3K, AKT, or mTOR pathways

- Prior treatment with exemestane (except adjuvant exemestane stopped >12 months prior
to start of study treatment as long as the patient did not recur during or within 12
months after the end of adjuvant exemestane)

- Evidence of visceral metastasis/es (i.e. liver, lung, peritoneal, pleural metastases,
malignant pleural effusions, malignant peritoneal effusions)

- History or evidence of metastatic disease to the brain

- Leptomeningeal carcinomatosis

- Any previous chemotherapy for HR+ HER2- metastatic breast cancer

- Radiotherapy within 4 weeks prior to the start of study treatment

- Use of concomitant systemic sex hormone therapy

- History or presence of cardiovascular abnormalities

- Known pre-existing interstitial lung disease

- Further exclusion criteria apply
We found this trial at
11
sites
250 25th Ave N, Ste 100
Nashville, Tennessee 37023
615-320-5090
Phone: +001 (615) 329-7274
Tennessee Oncology, PLLC Since 1976 Tennessee Oncology has been providing quality cancer care. In 2013,...
?
mi
from
Nashville, TN
Click here to add this to my saved trials
3840 Broadway
Fort Myers, Florida 33901
(239) 275-6400
Phone: +001 (239) 940-6890
?
mi
from
Fort Myers, FL
Click here to add this to my saved trials
Charlotte, North Carolina 28207
Phone: +001 (704) 342 1900
?
mi
from
Charlotte, NC
Click here to add this to my saved trials
Fort Worth, Texas 76104
Phone: +001 (817) 759-7000
?
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Goodyear, Arizona 85338
Phone: +001 (623) 207 3000
?
mi
from
Goodyear, AZ
Click here to add this to my saved trials
Kansas City, Missouri 64132
Phone: +001 (816) 276 4700
?
mi
from
Kansas City, MO
Click here to add this to my saved trials
Nyack, New York 10960
Phone: +001 (845) 480-7440
?
mi
from
Nyack, NY
Click here to add this to my saved trials
Philadelphia, Pennsylvania 19124
Phone: +001 (215) 537 7400
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Richmond, Virginia 23235
Phone: +001 (804) 287-3000
?
mi
from
Richmond, VA
Click here to add this to my saved trials
Tulsa, Oklahoma 74133
Phone: +001 (918) 286 5000
?
mi
from
Tulsa, OK
Click here to add this to my saved trials
Tweed Heads, New South Wales 2485
Phone: 61755067478
?
mi
from
Tweed Heads,
Click here to add this to my saved trials